Literature DB >> 23441952

Differential effects of retinoids and inhibitors of ERK and p38 signaling on adipogenic and myogenic differentiation of P19 stem cells.

Frédéric Bouchard1, Joanne Paquin.   

Abstract

All-trans-retinoic acid (atRA) is an essential signaling molecule in embryonic development. It regulates cell differentiation by activating nuclear retinoic acid receptors (RAR) and retinoid-X receptors (RXR), which both control gene expression. In addition, atRA could act in the cytoplasm by modulating the activity of mitogen-activated protein kinases (MAPK) ERK and p38, which also have a role in cell differentiation. AtRA can induce the differentiation of P19 embryonic carcinoma stem cells into adipocytes, cardiomyocytes, and skeletal muscle cells, concurrently, in the same culture. We postulated that combinations of atRA, atRA analogs exhibiting selectivity for RAR or RXR, and inhibitors of ERK and p38 signaling (ERKi and p38i) could be used to favor one mesodermal fate over the others in the P19 model. In a first series of experiments, we replaced atRA by an agonist of RXR (LG100268) or RAR (TTNPB) to preferentially stimulate one group of receptors over the other. LG100268 was as adipogenic and myogenic as atRA, whereas TTNPB strongly induced adipogenesis, but not myogenesis. ERKi enhanced the myogenic action of atRA, and p38i increased both adipogenesis and myogenesis. In a second series of experiments, we combined atRA with an RAR or RXR antagonist (RARatg or RXRatg) to preferentially deactivate each receptor group in turn. The combinations atRA+RXRatg and atRA+RARatg, including or not ERKi, had similar mesodermal actions as atRA. In contrast, there was no myogenesis with atRA+RXRatg+p38i treatment, and there were no myogenesis and no adipogenesis with the atRA+RARatg+p38i combination. Overall, the results indicate that p38 has a role in mesodermal differentiation that depends on the retinoid context. Indeed, p38 in conjunction with RXR is important in myogenesis, and p38 and RAR in adipogenesis. Under the conditions tested, it was possible to stimulate adipogenesis with a block on myogenesis, whereas increased myogenesis was accompanied by adipogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23441952      PMCID: PMC3699902          DOI: 10.1089/scd.2012.0209

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  60 in total

Review 1.  Potential of embryonic stem cells.

Authors:  A M Wobus
Journal:  Mol Aspects Med       Date:  2001-06

2.  Hsp25 and the p38 MAPK pathway are involved in differentiation of cardiomyocytes.

Authors:  S M Davidson; M Morange
Journal:  Dev Biol       Date:  2000-02-15       Impact factor: 3.582

3.  Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation.

Authors:  Maurizio Giannì; Annie Bauer; Enrico Garattini; Pierre Chambon; Cécile Rochette-Egly
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

4.  Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage.

Authors:  Frédéric Bost; Leslie Caron; Irène Marchetti; Christian Dani; Yannick Le Marchand-Brustel; Bernard Binétruy
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

5.  Mitogen-activated protein kinases and activator protein 1 are required for proliferation and cardiomyocyte differentiation of P19 embryonal carcinoma cells.

Authors:  Minna Eriksson; Sirpa Leppä
Journal:  J Biol Chem       Date:  2002-03-07       Impact factor: 5.157

Review 6.  Retinoids in embryonal development.

Authors:  S A Ross; P J McCaffery; U C Drager; L M De Luca
Journal:  Physiol Rev       Date:  2000-07       Impact factor: 37.312

7.  A p38 inhibitor allows to dissociate differentiation and apoptotic processes triggered upon LIF withdrawal in mouse embryonic stem cells.

Authors:  D Duval; M Malaisé; B Reinhardt; C Kedinger; H Boeuf
Journal:  Cell Death Differ       Date:  2004-03       Impact factor: 15.828

8.  Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes.

Authors:  Joanne Paquin; Bogdan A Danalache; Marek Jankowski; Samuel M McCann; Jolanta Gutkowska
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

Review 9.  The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death.

Authors:  H S Ahuja; A Szanto; L Nagy; P J A Davies
Journal:  J Biol Regul Homeost Agents       Date:  2003 Jan-Mar       Impact factor: 1.711

10.  RXR-induced TNF-alpha suppression is reversed by morphine in activated U937 cells.

Authors:  Liping Mou; Pamela Lankford-Turner; Michelle V Leander; Reid P Bissonnette; Robert M Donahoe; Walter Royal
Journal:  J Neuroimmunol       Date:  2004-02       Impact factor: 3.478

View more
  4 in total

1.  Retinoids Regulate Adipogenesis Involving the TGFβ/SMAD and Wnt/β-Catenin Pathways in Human Bone Marrow Mesenchymal Stem Cells.

Authors:  Jun Cao; Yuhong Ma; Weiqi Yao; Xiaoye Zhang; Dongcheng Wu
Journal:  Int J Mol Sci       Date:  2017-04-15       Impact factor: 5.923

2.  All-trans retinoic acid changes muscle fiber type via increasing GADD34 dependent on MAPK signal.

Authors:  Yuichiro Adachi; Masashi Masuda; Iori Sakakibara; Takayuki Uchida; Yuki Niida; Yuki Mori; Yuki Kamei; Yosuke Okumura; Hirokazu Ohminami; Kohta Ohnishi; Hisami Yamanaka-Okumura; Takeshi Nikawa; Yutaka Taketani
Journal:  Life Sci Alliance       Date:  2022-03-22

3.  N-acetyl cysteine prevents arecoline-inhibited C2C12 myoblast differentiation through ERK1/2 phosphorylation.

Authors:  Yi-Xuan Li; Chun-Hung Hsiao; Yung-Fu Chang
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

4.  Neonatal vitamin A injection promotes cattle muscle growth and increases oxidative muscle fibers.

Authors:  Bo Wang; Wei Nie; Xing Fu; Jeanene M de Avila; Yannan Ma; Mei-Jun Zhu; Martin Maquivar; Steven M Parish; Jan R Busboom; Mark L Nelson; Min Du
Journal:  J Anim Sci Biotechnol       Date:  2018-11-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.